Research status of atezolizumab combined with bevacizumab plus chemotherapy for the treatment of advanced non-small cell lung cancer
10.13699/j.cnki.1001-6821.2024.17.028
- VernacularTitle:阿替利珠单抗联合贝伐珠单抗、化疗治疗晚期非小细胞肺癌的研究现状
- Author:
Hou-Yun LAI
1
;
Yan LIANG
;
Feng LI
;
Jin ZHOU
;
Yan CHEN
;
Yi-Xin WANG
Author Information
1. 电子科技大学医学院附属肿瘤医院·四川省肿瘤医院,药学部,四川成都 610041;电子科技大学医学院,四川成都 610054
- Keywords:
anti-angiogenic drug;
non-small cell lung cancer;
immunotherapy;
combination therapy
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(17):2591-2595
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy had completely changed the treatment for patients with advanced non-small cell lung cancer.However,due to its low response rate as a monotherapy,many patients had not been able to benefit from the treatment.The combination of immunotherapy with anti-angiogenic drugs and chemotherapy might have helped to address this issue,and the regimen of atezolizumab with bevacizumab,carboplatin,and paclitaxel(ABCP)had been approved as a first-line treatment for advanced metastatic non-small cell lung cancer,holding great potential for application.This review had summarized the antitumor mechanisms of the ABCP regimen,had concluded the current status of its clinical application for different subgroups and treatment sequences,the safety and cost-effectiveness of the regimen,as well as the possibilities for alternative drug choices within the ABCP regimen and the development of new drugs,providing a reference for the personalized application of the ABCP regimen in patients with non-small cell lung cancer.
